Ticker PDUFA Timeline
RHHBY PDUFA Calendar: FDA Decision Dates & Catalyst Timeline
This page gathers active PDUFA and FDA decision milestones connected to Roche Holdings AG. Use it as a ticker-specific regulatory timeline, then open the company profile for recent news, stock data, sector context, and related catalysts.
Last updated: 2026-10-01
FDA calendar
Next FDA decisions
TECENTRIQ (atezolizumab) and TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) plus chemotherapy
Adjuvant treatment of stage III dMMR/MSI-H colon cancer · Patients with resected stage III deficient DNA mismatch repair or microsatellite instability-high colon cancer
ENSPRYNG (satralizumab)
Moderate-to-severe thyroid eye disease · Adults with moderate-to-severe active thyroid eye disease
Company context
PDUFA events are easier to interpret when they sit beside the latest company news and stock context.
Related BioPharmSignal pages
Frequently asked questions
What does the RHHBY PDUFA calendar show?
It shows active PDUFA and FDA decision milestones associated with RHHBY, including decision dates, application stage, and summary details when available.
Where can I find more context for RHHBY?
Use the BioPharmSignal company page for RHHBY to read related news, stock data, sector context, and company-specific updates.
Are these dates investment advice?
No. PDUFA dates are research inputs, not investment recommendations. Always review primary sources and understand the clinical and regulatory context.